# James Hardiman

> James Hardiman is a General Partner at DCVC (Data Collective Venture Capital), a deep tech-focused VC firm based in Palo Alto. A physicist by training with a BS in Engineering Physics from UC Berkeley and an MBA from University of Chicago Booth, he has been investing at DCVC since 2013 - backing companies at the intersection of hard science and transformative industry applications. His portfolio spans AI-native biotech, quantum computing, industrial robotics, and advanced materials, with board seats at companies including Lumafield, Q-CTRL, NOETIK, and Slip Robotics. Promoted to General Partner in July 2023, Hardiman brings a rare combination of hands-on technical experience (Lam Research, semiconductor processing) and strategic consulting chops (ZS Associates in healthcare/biotech, Blackstone in M&A) to his work as a deep tech investor.

- **Role:** General Partner at DCVC
- **Organizations:** DCVC, Creative Destruction Lab
- **Nationality:** American
- **Education:** Bachelor of Science, Engineering Physics, University of California, Berkeley, Master of Business Administration (MBA), University of Chicago Booth School of Business
- **Known for:** Promoted to General Partner at DCVC in July 2023, 20+ portfolio company board seats across biotech, robotics, quantum computing, and industrial AI, Led DCVC investments in Lumafield, Q-CTRL, NOETIK, Valar Labs, Slip Robotics, Alta Resource Technologies, and more

## Career timeline

- **2005-2007** — Technical Intern at Lam Research (semiconductor processing equipment)
- **2007-2012** — Consultant at ZS Associates (data-driven sales and marketing strategy for healthcare and biotech companies)
- **2012-2014** — MBA at University of Chicago Booth School of Business; Summer Associate at The Blackstone Group (M&A advisory)
- **2013** — Joined DCVC as an investor, shortly after the firm's first institutional fund
- **2014** — Full-time investing at DCVC; focus on AI, biotech, robotics, and quantum computing
- **2018** — Mentor at Creative Destruction Lab (Toronto), AI and Neuro streams
- **2020** — Board Director at Lumafield (3D industrial imaging); Board Director at stealth robotics company
- **2021** — Board Observer at Amogy (clean energy / ammonia decarbonization)
- **2023** — Promoted to General Partner at DCVC alongside Alan Cohen, Jason Pontin, and Ali Tamaseb
- **2025** — Led investment in Alta Resource Technologies (protein-based critical minerals production, $10M seed round)
- **2026** — Published analysis on Valar Labs' AI-derived biomarker for pancreatic cancer treatment; commentary on NOETIK-GSK licensing deal

## Achievements

- Promoted to General Partner at DCVC in July 2023
- 20+ portfolio company board seats across biotech, robotics, quantum computing, and industrial AI
- Led DCVC investments in Lumafield, Q-CTRL, NOETIK, Valar Labs, Slip Robotics, Alta Resource Technologies, and more
- Fund size of $725M under management at DCVC
- Mentor at Creative Destruction Lab for AI and Neuro streams
- Backing of Recursion Pharmaceuticals - a landmark AI-driven drug discovery company
- Identified quantum computing opportunity at Q-CTRL, a pioneer in quantum error suppression

## Latest updates

- **2026-02** — Published analysis on Valar Labs' AI-derived biomarker breakthrough for pancreatic cancer treatment on DCVC blog
- **2026-01** — Commentary on NOETIK's partnership with GSK validating AI licensing as a business model in TechBio
- **2025-10** — Covered Remedy's AI-powered robot supporting the world's first remote neurointervention procedure
- **2025-05** — Led investment in Alta Resource Technologies' $10M seed round for protein-based critical minerals production
- **2023-07** — Promoted to General Partner at DCVC

## Links

- Website: https://dcvc.com/team/james-hardiman/
- LinkedIn: http://www.linkedin.com/in/hardimanjames
- Twitter/X: https://twitter.com/hardimanjames
- Facebook: https://facebook.com/dcvc

---

Profile page: https://yespress.io/james-hardiman
Published by YesPress — https://yespress.io
Last updated: 2026-05-18